Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Q4 2022 Earnings Conference Call March 13, 2023 8:30 AM ET Lisa Wilson - Investor Relations Brian Cahill - Chief Financial Officer Brandon Folkes - Cantor Fitzgerald David Amsellem - Piper Sandler Good morning, everyone. My name is Todd, and I'll be your conference operator. At this time, I'd like to welcome everyone to Eagle Pharmaceuticals Fourth Quarter and Full-Year 2022 Financial Results [Technical Difficulty]. All lines have been placed on mute to prevent any ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |----------------------------------------------------------------------------|-------------------------------------------------------------------------|------------------------ ...

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Q3 2022 Earnings Conference Call November 7, 2022 8:30 AM ET Company Participants Lisa Wilson - Investor Relations Scott Tarriff - President & Chief Executive Officer Brian Cahill - Chief Financial Officer Conference Call Participants Tim Lugo - William Blair Brandon Folkes - Cantor Fitzgerald David Amsellem - Piper Sandler Operator Good morning, everyone. My name is Todd and I'll be your conference operator. At this time, I'd like to welcome everyone to Eagle Pharm ...

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Lisa Wilson – Investor Relations Scott Tarriff – President and Chief Executive Officer Mike Greenberg – Vice President-Medical Affairs Brian Cahill – Chief Financial Officer Conference Call Participants Lachlan Hanbury-Brown – William Blair David Amsellem – Piper Sandler Operator Good morning, everyone. My name is Katie and I will be your conference operator. At this time, I would like t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | |----------------------------------------------------------------------------|---------------------------------------------|--------------------------------------------------- ...

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Q1 2022 Earnings Conference Call May 9, 2022 8:30 AM ET Company Participants Lisa Wilson - IR Scott Tarriff - Founder, President, CEO & Director Brian Cahill - CFO Conference Call Participants Brandon Folkes - Cantor Fitzgerald & Co. Lachlan Hanbury-Brown - William Blair & Company David Amsellem - Piper Sandler & Co. Operator Good morning, everyone. My name is Gretchen, and I'll be your conference operator. At this time, I'd like to welcome everyone to Eagle Pharmac ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | |----------------------------------------------------------------------------|---------------------------------------------|-------------------------------------------------- ...

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Q4 2021 Earnings Conference Call March 7, 2022 8:30 AM ET Company Participants Lisa Wilson - Investor Relations Scott Tarriff - Founder, Chief Executive Officer, President Brian Cahill - Chief Financial Officer Conference Call Participants Tim Lugo - William Blair Brandon Folkes - Cantor Fitzgerald David Amsellem - Piper Sandler Operator Good morning, everyone. My name is Ashley, and I'll be your conference operator. At this time, I'd like to welcome everyone to Eag ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-36306 Eagle Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 2834 20-8179278 (State or Other J ...

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Q3 2021 Earnings Conference Call November 9, 2021 8:30 AM ET Company Participants Lisa Wilson - Investor Relations Scott Tariff - Chief Executive Officer Brian Cahill - Chief Financial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald David Amsellem - Piper Sandler Tim Lugo - William Blair Operator Good morning everyone. My name is Ashley, and I will be your conference Operator today. At this time, I would like to welcome everyone to Eagle Phar ...